Cargando…

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia

AIMS: Paliperidone palmitate 3-month (PP3M) represents a new long-acting injectable antipsychotic therapeutic option. This review aims: 1) to summarize available data relating to efficacy, safety, tolerability and costs of PP3M; 2) to describe hospitalization rate, occupational status, treatment pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brasso, Claudio, Bellino, Silvio, Bozzatello, Paola, Montemagni, Cristiana, Rocca, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683787/ https://www.ncbi.nlm.nih.gov/pubmed/29158676 http://dx.doi.org/10.2147/NDT.S150568

Ejemplares similares

Second Generation Long-Acting Injectable Antipsychotics in Schizophrenia: The Patient’s Subjective Quality of Life, Well-Being, and Satisfaction
por: Brasso, Claudio, et al.
Publicado: (2023)

The relative contributions of insight and neurocognition to intrinsic motivation in schizophrenia
por: Brasso, Claudio, et al.
Publicado: (2022)

Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review
por: Brasso, Claudio, et al.
Publicado: (2023)

Primary Psychosis: Risk and Protective Factors and Early Detection of the Onset
por: Brasso, Claudio, et al.
Publicado: (2021)

Models Predicting Psychosis in Patients With High Clinical Risk: A Systematic Review
por: Montemagni, Cristiana, et al.
Publicado: (2020)

Real-World Functioning in Psychiatric Outpatients: Predictive Factors
por: Bozzatello, Paola, et al.
Publicado: (2022)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni, Cristiana, et al.
Publicado: (2016)

The Role of Cognitive Deficits in Borderline Personality Disorder with Early Traumas: A Mediation Analysis
por: Bozzatello, Paola, et al.
Publicado: (2023)

The Impact of SARS-CoV-2 Infection on Youth Mental Health: A Narrative Review
por: Brasso, Claudio, et al.
Publicado: (2022)

The Management of Prodromal Symptoms of Bipolar Disorder: Available Options and Future Perspectives
por: Del Favero, Elisa, et al.
Publicado: (2021)

Pharmacological Treatment for Social Cognition: Current Evidence
por: Riccardi, Cecilia, et al.
Publicado: (2021)

Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability
por: Bellino, Silvio, et al.
Publicado: (2011)

Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study
por: Montemagni, Cristiana, et al.
Publicado: (2022)

Polyunsaturated Fatty Acids: What is Their Role in Treatment of Psychiatric Disorders?
por: Bozzatello, Paola, et al.
Publicado: (2019)

Mental Health in Childhood and Adolescence: The Role of Polyunsaturated Fatty Acids
por: Bozzatello, Paola, et al.
Publicado: (2021)

Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review
por: Bozzatello, Paola, et al.
Publicado: (2019)

Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France
por: Druais, Sylvain, et al.
Publicado: (2016)

Once-monthly paliperidone injection for the treatment of schizophrenia
por: Bishara, Delia
Publicado: (2010)

Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia
por: Oh, Jihoon, et al.
Publicado: (2023)

The Role of Trauma in Early Onset Borderline Personality Disorder: A Biopsychosocial Perspective
por: Bozzatello, Paola, et al.
Publicado: (2021)

Early Detection and Outcome in Borderline Personality Disorder
por: Bozzatello, Paola, et al.
Publicado: (2019)

Borderline Personality Disorder: Risk Factors and Early Detection
por: Bozzatello, Paola, et al.
Publicado: (2021)

Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults
por: Kim, Shiyun, et al.
Publicado: (2012)

Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain
por: Gutiérrez‐Rojas, Luis, et al.
Publicado: (2022)

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
por: Corbeil, Olivier, et al.
Publicado: (2022)

The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection
por: Stump, Trevor A., et al.
Publicado: (2021)

Effects of Omega 3 Fatty Acids on Main Dimensions of Psychopathology
por: Bozzatello, Paola, et al.
Publicado: (2020)

Efficacy of Polyunsaturated Fatty Acids (PUFAs) on Impulsive Behaviours and Aggressiveness in Psychiatric Disorders
por: Bellino, Silvio, et al.
Publicado: (2021)

Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
por: Mahlich, Jörg, et al.
Publicado: (2015)

Interpersonal Psychotherapy as a Single Treatment for Borderline Personality Disorder: A Pilot Randomized-Controlled Study
por: Bozzatello, Paola, et al.
Publicado: (2020)

Editorial: Borderline Personality Disorders in Adolescents: Clinical Challenges and Recent Advances
por: Bellino, Silvio, et al.
Publicado: (2022)

A case report of pregnancy and paliperidone palmitate 3‐monthly long‐acting injection
por: de Azevedo Avelar, Rita, et al.
Publicado: (2020)

The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly: Clinical Pharmacokinetic Evaluation in Patients With Schizophrenia (Preliminary Data)
por: Mauri, Massimo Carlo, et al.
Publicado: (2022)

Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal
por: García-Carmona, Juan Antonio, et al.
Publicado: (2023)

Benefit–risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia
por: Levitan, Bennett, et al.
Publicado: (2016)

Early Australian experience in the maintenance of schizophrenia management with 3-monthly paliperidone palmitate
por: Pai, Nagesh, et al.
Publicado: (2018)

Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia
por: Carpiniello, Bernardo, et al.
Publicado: (2016)

Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review
por: Edinoff, Amber N., et al.
Publicado: (2021)

Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review
por: González-Rodríguez, Alexandre, et al.
Publicado: (2015)

Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia
por: Basu, Anirban, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_239c3l4v07co3hfs82t144c5ts